LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Molecular Label to Help Develop Simpler and Faster Tuberculosis Tests

By LabMedica International staff writers
Posted on 06 May 2025
Print article
Image: Macrophages infected with mycobacterium tuberculosis (Photo courtesy of MIT)
Image: Macrophages infected with mycobacterium tuberculosis (Photo courtesy of MIT)

Tuberculosis (TB), the deadliest infectious disease globally, is responsible for infecting an estimated 10 million people each year and causing over 1 million deaths annually. While chest X-rays and molecular diagnostics are highly accurate, they are not always accessible in developing nations, where TB rates are high. In these countries, TB is frequently diagnosed by culturing microbes from sputum samples, but this method has a high false negative rate and can be challenging for patients, especially children, to provide a sample. Furthermore, this test requires several weeks for the bacteria to grow, which delays diagnosis. Once the bacteria are in the lungs, their thick cell wall helps them resist the host immune system. This cell wall is largely made up of complex sugar molecules called glycans, but understanding how these glycans defend the bacteria has been difficult. One of the challenges is the lack of an easy method to label these glycans within the cells. Chemists have now overcome this challenge by demonstrating that they can label a specific glycan called ManLAM using an organic molecule that reacts with sulfur-containing sugars. These sugars are found in only three bacterial species, with Mycobacterium tuberculosis, the causative agent of TB, being the most common and problematic.

After successfully labeling the glycan, researchers from the Massachusetts Institute of Technology (MIT, Cambridge, MA, USA) showed that they could track the bacteria as they infected macrophages, immune cells involved in fighting infections. Some researchers studying TB had speculated that the bacterial cells shed ManLAM after entering a host cell and that these free glycans interacted with the host immune system. However, the MIT team discovered that the glycan remains part of the bacterial cell wall for at least the first few days of infection. Moving forward, the researchers plan to use this technique to examine the behavior of the bacteria following antibiotic treatment or immune stimulation of macrophages. This approach could also be useful in studying the assembly of the bacterial cell wall and understanding how ManLAM aids in the bacteria’s entry into macrophages and other cells.

The researchers aim to use this approach to develop a diagnostic method capable of detecting TB-associated glycans, either in cultures or urine samples. Such a test could offer a more affordable and quicker alternative to existing diagnostics. Currently, there is a diagnostic under development that uses antibodies to detect ManLAM in urine samples, but this test is most effective in patients with active TB, particularly those who are immunosuppressed due to HIV or other conditions. By using their small-molecule sensor instead of antibodies, the MIT team hopes to create a more sensitive test that can detect even small amounts of ManLAM in urine samples.

“There aren’t a lot of good diagnostic options, and there are some patient populations, including children, who have a hard time giving samples that can be analyzed. There’s a lot of impetus to develop very simple, fast tests,” said Laura Kiessling, the Novartis Professor of Chemistry at MIT and the senior author of the study.

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
PSA Test
Humasis PSA Card
New
FOB+Transferrin+Calprotectin+Lactoferrin Test
CerTest FOB+Transferrin+Calprotectin+Lactoferrin Combo Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more